Results 181 to 190 of about 35,703 (223)

The Roles of PCSK9 in Alzheimer's Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence. [PDF]

Life (Basel)
Suswidiantoro V, Puteri MU, Kato M, Ariestanti DM, James RJ, Saputri FC.   +5 more
europepmc   +1 more source

Utility of Novel Lipid Parameters for Risk Stratification in Patients with Diabetes and STEMI-from a Prospective Study. [PDF]

Vasc Health Risk Manag
Zhao X, Chen R, Li J, Zhou J, Li N, Xue L, Yan S, Liu C, Zhou P, Chen Y, Song L, Zhao H, Yan H.   +12 more
europepmc   +1 more source

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. [PDF]

Eur Heart J Qual Care Clin Outcomes
Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J.   +6 more
europepmc   +1 more source

Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression. [PDF]

J Immunother Cancer
Hu C, Qin M, Lai W, Zhou H, Yuan C, Liu Y, Dai Y, Yang M, Hu M, Wang X, Luo M, Zhang R, Li G.   +12 more
europepmc   +1 more source

PCSK9 inhibitors improve lipid profile and hepatic steatosis surrogate indicators in patients with MAFLD and type 2 diabetes. [PDF]

Front Med (Lausanne)
Zhou Q, Liu X, Tang Y, Pan C, Bi X.
europepmc   +1 more source

Gene Editing Therapies Targeting Lipid Metabolism for Cardiovascular Disease: Tools, Delivery Strategies, and Clinical Progress. [PDF]

Cells
Ren Z, Zhou J, Yang D, Guo Y, Zhang J, Xu J, Chen YE.   +6 more
europepmc   +1 more source

Genetic determinants of plasma lipids in Greenlanders. [PDF]

Curr Opin Lipidol
Hjerresen J, Jørsboe E, Andersen MK.
europepmc   +1 more source

Targeting Pathways Implicated in Cholesterol Metabolism for Novel Cancer Therapy. [PDF]

Cancers (Basel)
Zhou Y, Sharma V, Li X, Singla RK, Kumar A, Kyada A, Ballal S, Nathiya D, Koul A, Khalid M, Gulati M, Arora S, Behl T, Kavalakatt J, Shen B, Bishayee A.   +15 more
europepmc   +1 more source

Medication adherence to lipid-lowering agents after percutaneous coronary intervention: nationwide real-world data in the Netherlands. [PDF]

Neth Heart J
Timmermans MJC, Witvliet MP, van Erkelens JA, Reitsma J, Kamphuisen PW, Camaro C, Danse PW, Arkenbout EK, PCI Registration Committee of the Netherlands Heart Registration.   +8 more
europepmc   +1 more source

Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR-α: Mechanistic Insights and Therapeutic Implications. [PDF]

Cardiovasc Ther
Alshammari SO, Shahzad N, Malik MNH, Alshammari QA, Alshammari A, Al Kazman BSM, Atif M, Solre GFB.   +7 more
europepmc   +1 more source